Assessment of Serum Level of Squamous Cell Carcinoma Antigen II in Patients with Lichen Planus

N.M.Abdelsattar1, D.M.Al Habbak2, W.A.Abd Elhalim3, N.W.Mikhael4"


Lichen planus (LP) is a chronic mucocutaneous autoimmune inflammatory disorder of the stratified squamous epithelium that mostly affects middle-aged adults. No significant differences in the incidence for LP are noticed between male and female patients. Squamous cell carcinoma antigen (SCCA) is known as a tumor biomarker for various squamous cell tumors. It was first identified in the uterine cervix by Kato and Torigoe. Total SCCA comprises nearly identical proteins. Both SCCAI and II belong to the ovalbumin-serpin proteinase inhibitor family. The aim of this work was to assess the serum levels of SCCAII in patients with LP and compare it to its level in normal group. This was a case-control study conducted over a period of six months from September 2018 to march 2019 included 100 participants, 80 patients suffering from LP. In addition to 20 apparently healthy. Patients were selected from the outpatient clinic of Dermatology and Andrology Department of Benha University Hospitals and Kafr Shokr central hospital. We found that Serum levels of SCCAII were significantly higher in patients with LP compared to healthy control subjects. In conclusion, significant elevation of SSCCAII is associated with LP. Serum SCCAII may become a novel and useful biomarker for evaluating disease activity.

Key words

Lichen planus, Squamous cell carcinoma antigen II, Serum squamous cell carcinoma antigen II.